A clinical line of fourteen patient-specific peptide references in calibrated 3 ml pen system. Three therapeutic series for licensed medical professionals in the United States and Brazil.
Zephra is a clinical brand designed for physicians, medspas and clinics that refuse the anonymity of traditional compounding. Every pen has traceable origin, calibrated dose, identity. Every batch, documentation. Every partner, support.
Calibrated dose, continuous flow, patient experience that justifies the premium positioning of your clinic.
FDA-registered facility, USP <797> compliant, certificate of analysis per batch. You know exactly what you're prescribing — and you can show your patient.
Clinical support material, consistent identity and dedicated guidance so your practice delivers with authority.
Advanced line for longevity protocols, mitochondrial support and hormonal optimization.
Tripeptide-copper complex for regenerative protocols, dermal optimization and tissue repair.
Compounded through a 503A partnership with a facility registered with the FDA as a Drug Establishment, USP <797> compliant. Controlled cold chain from laboratory to your clinic. Every Zephra pen carries complete documentation of origin — full traceability provided to registered practices prior to first order.
Brazilian licensed physicians may prescribe Zephra references for individual patients who have obtained personal-use importation authorization from ANVISA through the SEI system. Zephra does not hold ANVISA marketing authorization and does not commercialize references in the Brazilian market. The SEI authorization is granted to the patient, on the basis of a valid medical prescription.
Two paths for licensed professionals: request the full technical catalog with pricing, or register your practice to start ordering directly.
Patient-specific compounding in calibrated pen system. 3 ml per pen, FDA-registered facility, USP <797> compliant. Full technical catalog available upon professional registration.
Two paths for licensed professionals: request the full technical catalog with pricing, or register your practice to start ordering directly.
Zephra is the brand. Compounding is performed under partnership with an FDA-registered facility licensed for the operations below. All registration data is publicly verifiable through the FDA Drug Establishment Current Registration Site.
Zephra references are compounded under a patient-specific prescription framework (FDA Section 503A of the Federal Food, Drug, and Cosmetic Act). The facility carries operations registered for labeling, manufacturing and packaging. Zephra functions as the brand owner and commercial entity. Full partnership documentation, batch certificates of analysis and operational compliance records are provided to registered practices prior to the first order — never made publicly available, to preserve clinical and commercial confidentiality.
FDA registration status of any facility can be independently verified at accessdata.fda.gov via the Drug Establishments Current Registration Site, using the FEI or DUNS number above.
Please read carefully. By accessing this site, you acknowledge and accept the terms below.
This website is intended exclusively for licensed medical professionals — physicians, nurse practitioners, physician assistants, pharmacists and authorized clinical entities (medical practices, medspas, longevity clinics, wellness centers operating under medical direction). Information contained herein is not directed to patients or the general public. If you are not a licensed medical professional, please exit this site.
All references displayed on this site are compounded preparations produced under Section 503A of the U.S. Federal Food, Drug, and Cosmetic Act. Compounded medications are not FDA-approved drug products. They are prepared based on patient-specific prescriptions issued by a licensed practitioner and are not subject to the FDA approval process applicable to commercial pharmaceutical products. Compounded preparations have not been evaluated by the FDA for safety, efficacy or quality.
Nothing on this site constitutes medical advice, diagnosis, treatment recommendation or clinical guidance. Information is provided to licensed professionals for educational and commercial reference purposes only. Prescribing decisions remain the sole responsibility of the treating physician. Zephra does not provide medical consultation to patients, does not establish patient relationships, and does not direct clinical care.
References on this site are described in terms of pharmacological class and clinical category only. No statement on this site should be interpreted as a claim of efficacy, safety, superiority or therapeutic equivalence to any FDA-approved commercial drug product. Any therapeutic outcome depends on individual patient factors, dosing protocol, clinical context and physician judgment.
Zephra does not market, position or describe its references as substitutes, equivalents or alternatives to commercial pharmaceutical products bearing protected trade names. Any reference to active ingredients (such as tirzepatide, semaglutide, retatrutide and others) is made strictly in scientific and pharmacological terms, without implying clinical equivalence to any branded drug.
Shipping to Brazilian patients is performed exclusively under the personal-use importation framework administered by ANVISA through its SEI authorization system, based on a valid prescription issued by a licensed Brazilian physician. Zephra does not hold ANVISA marketing authorization and does not commercialize its references in the Brazilian market. The SEI process is the responsibility of the prescribing physician and the patient; Zephra provides documentation support upon request.
To the maximum extent permitted by applicable law, Zephra, its affiliates, partners, officers and employees disclaim all liability for direct, indirect, incidental, consequential or special damages arising from the use of, or reliance upon, information presented on this site. The site is provided "as is" without warranty of any kind. Use of this site implies acceptance of these terms.
These terms, the operation of this site and any dispute arising from or relating to the access, use or content of this site shall be governed by the laws of the State of Florida, United States of America, without regard to conflict-of-law provisions. The exclusive venue for any judicial proceeding not subject to arbitration shall be the state or federal courts located in Orange County, Florida.
Any controversy, claim or dispute arising out of or relating to this site, these terms or any commercial relationship between the user and Zephra shall be resolved by binding arbitration administered by the American Arbitration Association under its Commercial Arbitration Rules, conducted in English, in Orlando, Florida. Judgment on the award may be entered in any court of competent jurisdiction. The user expressly waives any right to participate in class actions or representative proceedings.
Nothing on this site, nor any commercial relationship established with Zephra, creates an agency, partnership, joint venture, employment or franchise relationship between Zephra and any user, registered practice, prescribing physician or other party. Practices that order Zephra references act as independent professional entities and are solely responsible for their own clinical decisions, regulatory obligations and patient care.
If any provision of these terms is held to be invalid, illegal or unenforceable by a court of competent jurisdiction, such provision shall be modified to the minimum extent necessary to render it valid and enforceable; if such modification is not possible, the provision shall be severed. The remaining provisions shall continue in full force and effect.
Information submitted through registration forms is used exclusively for professional verification, commercial communication and order processing. Data is handled in compliance with applicable U.S. federal and state privacy regulations. Brazilian users are also covered by LGPD requirements where applicable. Zephra does not sell, share or commercialize professional data with third parties.
For legal inquiries, regulatory questions or compliance concerns, please contact contact@penzephra.com. For partnership and commercial inquiries, partner@penzephra.com.